Upgrade to SI Premium - Free Trial

RBC Capital on Acadia Pharmaceuticals (ACAD): 'We see a -1-2% stock move off the Nuplazid slight miss for 1Q23'

May 8, 2023 4:39 PM
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles